Divis Laboratories
BSE: 532488|NSE: DIVISLAB|ISIN: INE361B01024|SECTOR: Pharmaceuticals
754.50
-12.2 (-1.59%)
VOLUME 11,622
754.55
-12.8 (-1.67%)
VOLUME 149,420
| Company History - Divis Laboratories |
Milestones:
1990
-Divis Research Center (DRC) established.
1991-1993
-DRC successfully develops several commercial processes for
intermediates and bulk actives and supplies to manufacturing majors.
1994
-Divis Research Center changes its name to Divis Laboratories Limited
to reflect its growing area of operations and its plans to enter the
manufacturing sector in the following year.
1995
-Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts
operations.
1997
-SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002
compliant.
1999
-European Directorate gives a “Certificate of Suitability” (CoS) for
Naproxen produced at Divis Laboratories.
2000
-US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K
awards Divis the ISO 9001 Certification SGS International AG of
Switzerland awards Divis the ISO-14001 Certification (for its
efficient Environment Management Systems).
2001
-BVQI of London awards Divis the OHSAS-18001 Certification (for its
Occupational Health and Safety Management Systems).
2002
-Divis commences the setting up of its 2nd Manufacturing Facility
(Unit-2) at Chippada near Visakhapatnam.
2003
-Divis opens a new research center christened ‘DRC-Vizag’ for
fundamental research in selected niche business core segments.
-Went for IPO and listed on stock exchanges BSE, NSE and HSE.
-Divi's Laboratorie receives Certificate of Substantiability from
the council of Europe
-Appointed Mr A Narendra as Company Secretary & Compliance Officer of
the company (in place of outgoing Company Secretary Mr P Sudarshan)
who has joined the organization.
2004
- Divi'S Laboratories Limited has informed that the manufacturing
facility of Divi's Labs at Choutuppal near Hyderabad was successfully
inspected by US-FDA in May 2004.
-US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483.
2006
-Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE),
Hyderabad with effect from March 29, 2006.
-US-FDA inspects the Visakhapatnam(Unit-2) for the first time.
2007
- The Company has splits its face value from Rs10/- to Rs2/-.
2008
-Third US-FDA inspection for Choutuppal(Unit-1). |
 |
| Source : Dion Global Solutions Limited |
 |
Quick Links for Divis Laboratories
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.